
via RCSI
Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB). This work could offer a practical treatment that has the potential to be scaled-up and mass-produced for clinical testing.
The treatment, which patients will take using an inhaler, works by reducing the bacteria in the lungs that causes tuberculosis while also helping the patient’s immune system fight the disease.
There is only one vaccine for tuberculosis, developed in 1921. It is unreliable in preventing the most common form of TB, and is not suitable in all patient groups. The vaccine works best against specific forms of TB and is usually given to infants in at-risk populations.
Tuberculosis is one of the top 10 causes of death worldwide. The World Health Organization (WHO) data show that 10 million people fell ill with TB and 1.6 million died from the disease in 2017. WHO estimates that there were 558,000 new cases with resistance to the most effective first-line antibiotic. Of those resistant to the drug, 82% were resistant to multiple antibiotics.
Funded by the Health Research Board (HRB) and the Royal City of Dublin Hospital Trust, the research is published in the European Journal of Pharmaceutics & Biopharmaceutics.
The work, led by Dr Gemma O’Connor and Prof Sally-Ann Cryan in RCSI, was carried out in collaboration with research teams in St James Hospital, Trinity College Dublin and Imperial College London. Prof Joseph Keane and Dr Mary O’Sullivan led the team at St James Hospital and Trinity College Dublin with Dr Brian Robertson and Dr Nitya Krishnan leading the team at Imperial College London.
Multidrug-resistant TB (MDR-TB) is seen as both a public health crisis and a health security threat. Ending the TB epidemic by 2030 is listed among the health targets of the United Nations Sustainable Development Goals.
The pathogen that causes tuberculosis spreads by people breathing infected droplets into their lungs, where the disease can remain dormant or spread further. The research makes use of a derivative of Vitamin A called all trans retinoic acid, atRA, which previous studies have shown is an effective treatment for tuberculosis.
“Many cases of TB are now becoming resistant to existing antibiotics. This new treatment could be used alongside antibiotics to treat drug-resistant TB and also possibly reduce the rate of antibiotic resistance resulting from conventional antibiotic treatments,” said Prof Cryan, Associate Professor of Pharmaceutics in RCSI School of Pharmacy and the study’s senior author.
Using a spray-drying process, the researchers packaged atRA within safe-for-consumption particles that are small enough to use in an inhaler. These particles efficiently delivered the treatment and significantly reduced tuberculosis-causing bacteria and associated lung damage, which supports their potential for clinical testing.
“Unfortunately, tuberculosis remains a significant problem for world health. We urgently need innovative treatments like this one if we are to achieve the UN 2030 health targets,” said Prof Keane, Professor at Trinity College Dublin School of Medicine and Consultant Respiratory Physician in St James’s Hospital.
Learn more: RCSI researchers develop new tuberculosis treatment
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- A mission to conquer tuberculosis and sleeping sickness in developing nationson February 25, 2021 at 4:45 am
That enables the bacteria to develop drug resistance." There is no gene exchange between bacterial cells in Mycobacterium tuberculosis (MTB), so MTB obtains drug resistance when a point mutation ...
- Tuberculosis Testing Market With Upcoming Pricing Policies and Strategies(2022-2031)| Abbott Laboratories, Akonni Biosystems Inc., Alere Inc.on February 23, 2021 at 7:48 pm
Feb 24, 2021 (WiredRelease via Comtex) -- The latest research report provides a complete assessment of the Global Tuberculosis Testing market for the forecast year 2022-2031, which is beneficial for ...
- MUSC researcher awarded $9.9 million for tuberculosis treatment and preventionon February 23, 2021 at 12:10 pm
Susan Dorman, M.D., an infectious disease expert at the Medical University of South Carolina (MUSC), was recently awarded a 10-year, $9.9 million contract by the Centers for Disease Control and ...
- Investigation Finds Tuberculosis May Be Risk Factor for Behçet Diseaseon February 23, 2021 at 8:15 am
An analysis of human genetic and biomarker data found that tuberculosis was a risk factor for Behçet disease, a noninfectious uveitis condition.
- Scenario analysis for programmatic tuberculosis control in Bangladesh: a mathematical modelling studyon February 23, 2021 at 4:54 am
Tuberculosis (TB) is a major public health problem. Although the National TB control program of Bangladesh is implementing a comprehensive expansion of TB control st ...
- Aim to Eliminate Tuberculosis From Country By 2025, Says PM Modion February 22, 2021 at 11:20 pm
We aim to eliminate tuberculosis from the country by 2025. Wearing masks, early diagnosis and treatment are also important in its prevention, PM Modi said.
- A lemur died from tuberculosis. Here’s why that matters.on February 22, 2021 at 2:19 pm
The ring-tailed lemur was emaciated and suffering from advanced tuberculosis by the time she was turned over to the rescue facility in southwestern Madagascar in April 2019. An alarming, golf ...
- Study could explain tuberculosis bacteria paradoxon February 20, 2021 at 4:00 pm
Tuberculosis bacteria have evolved to remember stressful encounters and react quickly to future stress, according to a study by computational bioengineers and infectious disease experts.
- New biomarker predicts individual anti-tuberculosis treatment durationon February 20, 2021 at 10:51 am
When can tuberculosis therapy be stopped without risk of relapse? Doctors are faced with this question time and again, because the lack of detection of the tuberculosis pathogen Mycobacterium ...
- Tuberculosis: New biomarker indicates individual treatment durationon February 19, 2021 at 9:53 am
When can tuberculosis therapy be stopped without risk of relapse? Doctors are faced with this question time and again, because the lack of detection of the tuberculosis pathogen Mycobacterium ...
via Bing News